Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps
Novo Nordisk’s stock keeps falling even when the news is good, and CEO Mike Doustdar just admitted why. Eli Lilly is beating Novo at its own game. Doustdar sat down with CNBC’s Jim Cramer this week to explain the disconnect. Novo, famous for its GLP-1 medication Ozempic, raised its full-year sales guidance on August 4,…
